6 May 2021 07:31
6 May 2021 ASX Code: MXC LSE Code: MXC | MGC Pharmaceuticals Ltd ASX Trading Halt |
|
|
MGC Pharmaceuticals Ltd (ASX, LSE: MXC, 'MGC Pharma' or 'the Company') advises that trading in the shares of the Company have been halted on the Australian Securities Exchange ("ASX") effective from Thursday, 6 May 2021. The halt was requested by the Company pending the release of an announcement by the Company in relation to further findings on ArtemiCTM.
The trading halt will remain until the earlier of an announcement to the market regarding the above or the opening of trade on ASX on 10 May 2021.
Trading in the Company's ordinary securities will continue on LSE during this period.
.--Ends--
MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director +61 8 6382 3390 info@mgcpharma.com.au | UK PR Tavistock - Tavistock Tim Pearson +44 7983118 502 Tim.Pearson@tavistock.co.uk |
UK Broker - Turner Pope Andy Thacker info@TurnerPope.com
| Australian PR/IR Advisors - Media & Capital Partners Rod Hinchcliffe (IR) +61 412 277 377 Rod.Hinchcliffe@mcpartners.com.au |
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline.
Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.
MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.
MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.
Follow us through our social media channels
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma
MXC.L (MXC)